

SIDA Y ENFERMEDADES INFECCIOSAS

Abadia, M; Montes, M; Ponce, MD; Romero, M; Hernandez, T; Novo, J; Froilan, C; Gonzalo, N; Borocia, A; Garcia, A; Fernandez, R; Poza, J; Grau, PC; Erdozain, JC; Moreno, V; Valencia, E; Garcia-Samaniego, J; Martin-Carbonero, L; Gonzalez-Garcia, JJ; Oliveira, A. Management of hepatitis C-cirrhotic patients with basal large betablocked esophageal varices after sustained virological response. HEPATOLOGY. 2017; 66:247A-247A.Meeting Abstract. IF -13,246

Alsina, M; Martin-Ancel, A; Alarcon-Allen, A; Arca, G; Gaya, F; Garcia-Alix, A. The Severity of Hypoxic-Ischemic Encephalopathy Correlates With Multiple Organ Dysfunction in the Hypothermia Era. PEDIATRIC CRITICAL CARE MEDICINE. 2017; 18(3):234-240.Article. IF -3,495

Arribas, JR; DeJesus, E; van Lunzen, J; Zurawski, C; Doroana, M; Towner, W; Lazzarin, A; Nelson, M; McColl, D; Andreatta, K; Swamy, R; Szwarcberg, J; Nguyen, T. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. HIV CLINICAL TRIALS. 2017; 18(3):118-125.Article. IF -1,778

Arribas, JR; Thompson, M; Sax, PE; Haas, B; McDonald, C; Wohl, DA; DeJesus, E; Clarke, AE; Guo, S; Wang, H; Callebaut, C; Plummer, A; Cheng, A; Das, M; McCallister, S. Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2017; 75(2):211-218.Article. IF -3,935

Baker, JV; Sharma, S; Achhra, AC; Bernardino, JI; Bogner, JR; Duprez, D; Emery, S; Gazzard, B; Gordin, J; Grandits, G; Phillips, AN; Schwarze, S; Soliman, EZ; Spector, SA; Tambussi, G; Lundgren, J. Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. JOURNAL OF THE AMERICAN HEART ASSOCIATION. 2017; 6(5):-e004987.Article. IF -4,863

Berenguer, J; Rodriguez-Castellano, E; Carrero, A; Von Wichmann, MA; Montero, M; Galindo, MJ; Mallolas, J; Crespo, M; Ellez, MJT; Quereda, C; Sanz, J; Barros, C; Tural, C; Santos, I; Pulido, F; Guardiola, JM; Rubio, R; Ortega, E; Montes, ML; Jurdado, JJ; Gaspar, G; Esteban, H; Bellon, JEM; Gonzalez-Garcia, J. Eradication of Hepatitis C Virus and Non-Liver-Related Non-Acquired Immune Deficiency Syndrome-Related Events in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. HEPATOLOGY. 2017; 66(2):344-356.Article. IF -13,246

Eron, J; Margolis, D; Gonzalez-Garcia, J; Stellbrink, HJ; Yazdanpanah, Y; Podzamczek, D; Lutz, T; Angel, JB; Richmond, GJ; Clotet, B; Gutierrez, F; Sloan, L; Sutton, KC; Dorey, D; Smith, KY; Williams, PE; Spreen, WR. Safety and efficacy of long-acting CAB and RPV as two drug IM maintenance therapy: LATTE-2 week 96 results. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2017; 20:107-108.Meeting Abstract. IF -6,296

Garcia-Bujalance, S; Gutierrez-Arroyo, A; De la Calle, F; Diaz-Menendez, M; Arribas, JR; Garcia-Rodriguez, J; Arsuaga, M. Persistence and infectivity of Zika virus in semen after returning from endemic areas: Report of 5 cases. JOURNAL OF CLINICAL VIROLOGY. 2017; 96:110-115.Article. IF -3,051

Girard, PM; Antinori, A; Arribas, JR; Ripamonti, D; Bicer, C; Netze-Sveine, B; Hadacek, B; Moecklinghoff, C. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial. HIV MEDICINE. 2017; 18(1):5-12.Article. IF -3,257

Gonzalez-Baeza, A; Arribas, JR; Perez-Valero, I; Monge, S; Bayon, C; Martin, P; Rubio, S; Carvajal, F. Vocal emotion processing deficits in HIV-infected individuals. JOURNAL OF NEUROVIROLOGY. 2017; 23(2):304-312.Article. IF -3,206

Halperin, SA; Arribas, JR; Rupp, R; Andrews, CP; Chu, L; Das, R; Simon, JK; Onorato, MT; Liu, K; Martin, J; Helmond, FA. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. JOURNAL OF INFECTIOUS DISEASES. 2017; 215(12):1789-1798.Article. IF -6,273

Lazarus, JV; Barton, SE; Bernardino, JI. Taking the long-view in a personalised approach to HIV care. LANCET HIV. 2017; 4(11):E483-E485.Editorial Material. IF -47,831

Lopez, MMDLNM; Soto, CI; Gomez, RF; Ladreda, AA; De Antonio, IP; Bernardino, JI; Salicio, ER; Blanco, JJR; Moreno, M; Martinez, GG. Subclinical functional and structural cardiomyopathy among patients infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. EUROPEAN JOURNAL OF HEART FAILURE. 2017; 19:297-297.Meeting Abstract. IF -6,968

Lopez, MNM; Soto, CI; Gomez, RF; Ladreda, AA; De Antonio, IP; Salicio, ER; Moreno, M; Bernardino, JI; Blanco, JJR; Martinez, GG. High prevalence of subclinical right ventricle cardiomyopathy among patients infected with human immunodeficiency virus on highly active antiretroviral therapy. EUROPEAN JOURNAL OF HEART FAILURE. 2017; 19:22-22.Meeting Abstract. IF -6,968

Macias, J; Mancebo, M; Merino, D; Tellez, F; Montes-Ramirez, ML; Pulido, F; Rivero-Juarez, A; Raffo, M; Perez-Perez, M; Merchante, N; Cotarelo, M; Pineda, JA. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human

Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. CLINICAL INFECTIOUS DISEASES. 2017; 65(6):1012-1019.Article. IF -8,216

Margolis, DA; Gonzalez-Garcia, J; Stellbrink, HJ; Eron, JJ; Yazdanpanah, Y; Podzamczek, D; Lutz, T; Angel, JB; Richmond, GJ; Clotet, B; Gutierrez, F; Sloan, L; St Clair, M; Murray, M; Ford, SL; Mrus, J; Patel, P; Crauwels, H; Griffith, SK; Sutton, KC; Dorey, D; Smith, KY; Williams, PE; Spreen, WR. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. LANCET. 2017; 390(10101):1499-1510.Article. IF -47,831

McComsey, G; Gonzalez-Garcia, J; Lupo, S; De Wet, J; Parks, D; Kahl, L; Wynne, B; Gartland, M; Angelis, K; Cupo, M; Vandermeulen, K; Aboud, M. Sub-study 202094 of SWORD 1 & SWORD 2: switch from TDF containing regimen to DTG plus RPV improves bone mineral density and bone turnover markers over 48 weeks. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2017; 20:123-123.Meeting Abstract. IF -6,296

Montejano, R; Stella-Ascariz, N; Monge, S; Bernardino, JI; Perez-Valero, I; Montes, ML; Valencia, E; Martin-Carbonero, L; Moreno, V; Gonzalez-Garcia, J; Arnalich, F; Mingorance, J; Berniches, LP; Perona, R; Arribas, JR. Impact of Antiretroviral Treatment Containing Tenofovir Difumarate on the Telomere Length of Aviremic HIV-Infected Patients. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2017; 76(1):102-109.Article. IF -3,935

Montes, ML; Oliveira, A; Ahumada, A; Aldamiz, T; Garcia-Samaniego, J; Clemente, A; Berenguer, J; Gonzalez-Garcia, J; Martin-Carbonero, L. Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. AIDS. 2017; 31(9):1253-1260.Article. IF -5,003

Moreno, S; Antela, A; Garcia, F; del Amo, J; Boix, V; Coll, P; Fortuny, C; Sirvent, JLG; Gutierrez, F; Iribarren, JA; Llibre, JM; de Quiros, JCLB; Losa, JE; Lozano, A; Meulbroek, M; Olalla, J; Pujol, F; Pulido, F; Casal, MC; Garcia, JG; Aldeguer, JL; Molina, JAP; Palter, DP; Roman, AR. Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2017; 35(6):377-383.Article. IF -1,714

Negredo, A; de la Calle-Prieto, F; Palencia-Herrejon, E; Mora-Rillo, M; Astray-Mochales, J; Sanchez-Seco, MP; Lopez, EB; Menarguez, J; Fernandez-Cruz, A; Sanchez-Artola, B; Keough-Delgado, E; de Arellano, ER; Lasala, F; Milla, J; Fraile, JL; Gavin, MO; de la Gandara, AM; Perez, LL; Diaz-Diaz, D; Lopez-Garcia, MA; Delgado-Jimenez, P; Martin-Quiros, A; Trigo, E; Figueira, JC; Manzanares, J; Rodriguez-Baena, E; Garcia-Comas, L; Rodriguez-Fraga, O; Garcia-Arenzana, N; Fernandez-Diaz, MV; Cornejo, VM; Emmerich, P; Schmidt-Chanasit, J; Arribas, JR. Autochthonous Crimean-Congo Hemorrhagic Fever in Spain. NEW ENGLAND JOURNAL OF MEDICINE. 2017; 377(2):154-161.Article. IF -72,406

Orkin, Chloe; Molina, Jean-Michel; Negredo, Eugenia; Arribas, Jose R; Gathe, Joseph; Eron, Joseph J; Van Landuyt, Erika; Lathouwers, Erkki; Hufkens, Veerle; Petrovic, Romana; Vanveggel, Simon; Opsomer, Magda. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.. *lancet*. 2017:-.Article. IF -47,831

Perez-Molina, JA; Rubio, R; Rivero, A; Pasquau, J; Suarez-Lozano, I; Riera, M; Estebanez, M; Palacios, R; Sanz-Moreno, J; Troya, J; Marino, A; Antela, A; Navarro, J; Esteban, H; Moreno, S. Simplification to dual therapy (atazanavir/ritonavir plus lamivudine) versus standard triple therapy [atazanavir/ritonavir plus two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). *JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY*. 2017; 72(1):246-253.Article. IF -5,071

Pulido, F; Ribera, E; Lagarde, M; Perez-Valero, I; Palacios, R; Iribarren, JA; Payeras, A; Domingo, P; Sanz, J; Cervero, M; Curran, A; Rodriguez-Gomez, FJ; Tellez, MJ; Ryan, P; Barrufet, P; Knobel, H; Rivero, A; Alejos, B; Yllescas, M; Arribas, JR. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. *CLINICAL INFECTIOUS DISEASES*. 2017; 65(12):2112-2118.Article. IF -8,216

Rivero, A; Perez-Molina, JA; Blasco, AJ; Arribas, JR; Crespo, M; Domingo, P; Estrada, V; Iribarren, JA; Knobel, H; Lazaro, P; Lopez-Aldeguer, J; Lozano, F; Moreno, S; Palacios, R; Pineda, JA; Pulido, F; Rubio, R; de la Torre, J; Tuset, M; Gatell, JM. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. *ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA*. 2017; 35(2):88-99.Article. IF -1,714

Rosado-Sanchez, I; Herrero-Fernandez, I; Alvarez-Rios, AI; Genebat, M; Abad-Carrillo, MA; Ruiz-Mateos, E; Pulido, F; Gonzalez-Garcia, J; Montero, M; Bernal-Morell, E; Vidal, F; Leal, M; Pacheco, YM. A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects. *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY*. 2017; 61(8):-e00605-17.Article. IF -4,302

Saumoy, M; Llibre, JM; Terron, A; Knobel, H; Arribas, JR; Domingo, P; Arroyo-Manzano, D; Rivero, A; Moreno, S; Podzamczek, D. Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice. *AIDS RESEARCH AND HUMAN RETROVIRUSES*. 2017; 33(1):29-32.Article. IF -2,095

Sax, PE; Pozniak, A; Montes, ML; Koenig, E; DeJesus, E; Stellbrink, HJ; Antinori, A; Workowski, K; Slim, J; Reynes, J; Garner, W; Custodio, J; White, K; SenGupta, D; Cheng, A; Quirk, E. Coformulated bictegavir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. LANCET. 2017; 390(10107):2073-2082.Article. IF -47,831

Sobrinho-Jimenez, C; Jimenez-Nacher, I; Moreno-Ramos, F; Gonzalez-Fernandez, MA; Freire-Gonzalez, M; Gonzalez-Garcia, J; Herrero-Ambrosio, A. Analysis of antiretroviral therapy modification in routine clinical practice in the management of HIV infection. EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE. 2017; 24(2):96-100.Article. IF -0,718

Stella-Ascariz, N; Arribas, JR; Paredes, R; Li, JZ. The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure. JOURNAL OF INFECTIOUS DISEASES. 2017; 216():S847-S850.Article. IF -6,273

Stella-Ascariz, N; Montejano, R; Pintado-Berninches, L; Monge, S; Bernardino, JI; Perez-Valero, I; Montes, ML; Mingorance, J; Perona, R; Arribas, JR. Differential Effects of Tenofovir, Abacavir, Emtricitabine, and Darunavir on Telomerase Activity In Vitro. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2017; 74(1):91-94.Article. IF -3,935

Valencia-Ortega, ME; Garcia-Bujalance, S; Gonzalez-Garcia, J. Hepatitis with a multiple etiology in HIV-positive men who have sexual relations with other men. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. 2017; 109(11):801-.Letter. IF -1,401

Nº Documentos	Tipo de documento	FI	1º Cuartil	1º Decil
25	Artículos	310,195	17	11
1	Cartas	1,401	0	0
1	Editoriales	47,831	1	1
5	Meeting Abstract	39,774	5	5
	FI Originales	310,195		
	FI Total	399,201		